Achieved 16% organic non-COVID revenue growth in 2025, significantly outpacing the broader bioprocessing market through portfolio diversity and commercial execution. Performance was driven by exceptional strength in Proteins and Analytics, which both grew over 30% in Q4, offsetting muted demand for downstream capital equipment. Key account penetration strategy successfully increased product line adoption, with top customers now purchasing 2.5x more product lines compared to 2019 levels. Successfully ...